Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2 Overexpressing Solid Tumors

PR Newswire - Press Release

All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here

Study is designed to evaluate the potential for a synergistic effect of CAR-M therapy in combination with KEYTRUDA®

PHILADELPHIA, June 28, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq:CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced that the first patient has been dosed in its Phase I clinical trial that will test the safety and tolerability of the Company's lead product candidate, CT-0508, a human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-M) in combination with Merck's anti-PD1 therapy KEYTRUDA® (pembrolizumab) for the treatment of HER2 overexpressing cancers.

Read more at prnewswire.com

Related Symbols

Symbol Last Chg %Chg
CARM 0.0482 -0.0037 -7.13%
Carisma Therapeutics Inc

Most Popular News

Investor checking market data by SAI SU PAW KA via Shutterstock 1
Forget Nvidia and Broadcom. This Forgotten Retail Stock Is a Top Performer in 2025.
Double explosure with businesss charts and financial district of megapolis city by Golden Dayz via Shutterstock 2
Stocks Climb Before the Open on Micron Boost Ahead of U.S. Inflation Data
A close-up shot of Warren Buffett_ Image by mark reinstein via Shutterstock_ 3
‘We’ll Be in These Stocks 10, 20 Years’: Warren Buffett’s $30 Billion Bet Gets a Big Boost as Bank of Japan Raises Rates to 30-Year High
A Palantir sign displayed on an office building by Poetra_RH via Shutterstock 4
How Much You’d Have If You Bet $10,000 on Palantir Stock in January and 1 Key PLTR Catalyst to Watch in 2026
Image of Warren E_ Buffett by Photo Agency via Shutterstock 5
Warren Buffett Used to Give His Family Members $10,000 in Cash for Christmas – Why He Stopped, and What the Oracle of Omaha Left Under the Tree Instead
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot